PVC Clinical Trials & Post-Marketing Surveillance 3 — Questions and Answers
Question 1: A sponsor identifies a new, potentially serious risk for a drug under clinical development. Within how many calendar days must a SUSAR be reported to the FDA?
- 7 days for fatal/life-threatening; 15 days for other serious unexpected (Correct answer)
- 15 days for all serious unexpected adverse reactions
- 30 days for all serious adverse events
- 7 days for all SUSARs regardless of outcome
Correct answer: 7 days for fatal/life-threatening; 15 days for other serious unexpected
FDA regulations (21 CFR 312.32) require 7-day reporting for fatal or life-threatening SUSARs and 15-day reporting for other serious unexpected reactions.
Question 2: What distinguishes an 'unexpected' adverse drug reaction from an 'expected' one in the context of clinical trial safety reporting?
- Unexpected events occur more frequently than anticipated
- The nature or severity is not consistent with the Investigator's Brochure (Correct answer)
- The event was not predicted by the trial protocol
- Unexpected events are always serious
Correct answer: The nature or severity is not consistent with the Investigator's Brochure
An unexpected ADR is one whose nature, severity, or specificity is not consistent with the reference safety information in the Investigator's Brochure.
Question 3: In the context of post-marketing surveillance, what is a 'risk minimization measure' (RMM)?
- A post-marketing clinical trial designed to confirm efficacy
- An intervention to prevent or reduce the probability or severity of an adverse outcome (Correct answer)
- A regulatory labeling change triggered by a safety signal
- A voluntary withdrawal of a product from a specific market
Correct answer: An intervention to prevent or reduce the probability or severity of an adverse outcome
Risk minimization measures are interventions beyond standard labeling designed to prevent or reduce adverse reactions associated with a medicinal product.
Question 4: Which phase of clinical development is primarily designed to assess dose-response relationships and short-term safety in a larger patient population?
- Phase I
- Phase II (Correct answer)
- Phase III
- Phase IV
Correct answer: Phase II
Phase II trials evaluate efficacy, optimal dose ranges, and safety in the target patient population, typically enrolling hundreds of subjects.
Question 5: A pharmacovigilance team identifies a signal suggesting a cardiac risk with a newly marketed antibiotic. What is the typical sequence of signal management steps?
- Detection → Validation → Prioritization → Assessment → Recommendation (Correct answer)
- Detection → Assessment → Validation → Recommendation → Prioritization
- Validation → Detection → Assessment → Prioritization → Recommendation
- Detection → Prioritization → Validation → Recommendation → Assessment
Correct answer: Detection → Validation → Prioritization → Assessment → Recommendation
The ICH E2E signal management framework follows the sequence: detection, validation, prioritization, assessment, and recommendation for action.
Question 6: Under FDA regulations, which entity is primarily responsible for submitting post-marketing safety reports including 15-day Alert Reports?
- The prescribing physician
- The NDA/BLA holder (marketing authorization holder) (Correct answer)
- The clinical investigator
- The IRB or ethics committee
Correct answer: The NDA/BLA holder (marketing authorization holder)
The NDA or BLA holder bears primary regulatory responsibility for post-marketing pharmacovigilance, including 15-day expedited safety reports.
Question 7: A registry study enrolled 5,000 patients over 3 years following a drug's approval. This study design is best classified as:
- Randomized controlled trial
- Prospective cohort observational study (Correct answer)
- Case-control study
- Crossover study
Correct answer: Prospective cohort observational study
Disease or product registries follow defined cohorts prospectively over time and are classified as observational cohort studies.
PVC Clinical Trials & Post-Marketing Surveillance 3
A sponsor identifies a new, potentially serious risk for a drug under clinical development.
Within how many calendar days must a SUSAR be reported to the FDA?